Grifols Overview

  • Founded
  • 1909
Founded
  • Status
  • Public
  • Employees
  • 24,000
Employees
  • Stock Symbol
  • GRF
Stock Symbol
  • Investments
  • 33
  • Share Price
  • $27.40
  • (As of Friday Closing)

Grifols General Information

Description

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 78% of sales in 2019. Grifols also has smaller segments including diagnostics, hospital supplies, and biosupplies. Diagnostics is now roughly 14% of revenue following the Novartis and Hologic deals.

Contact Information

Website
Formerly Known As
Probitas Pharma
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Diagnostic Equipment
Stock Exchange
XMAD
Primary Office
  • Avinguda de la Generalitat, 152
  • Parc empresarial Can Sant Joan, Sant Cugat del Vallès
  • 08174 Barcelona
  • Spain
+34 935 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Grifols Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$27.40 $28.14 $22.73 - $36.79 $16.3B 682M 1.12M $1.03

Grifols Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 26,531,860 26,531,860 28,721,160 22,579,720
Revenue 6,087,178 6,087,178 5,707,703 5,294,632
EBITDA 1,613,047 1,613,047 1,488,573 1,433,330
Net Income 705,089 705,089 699,816 704,077
Total Assets 18,787,469 18,787,469 17,410,399 14,272,530
Total Debt 8,500,792 8,500,792 7,960,938 8,098
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Grifols Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Grifols‘s full profile, request access.

Request a free trial

Grifols Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sel
Biotechnology
Barcelona, Spain
24,000 As of 2021
000000000

00000 00

erit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidat
000000000000000
Basel, Switzerland
000000 As of 0000
00000
00.00 0000-00-00
00000000000

00000

eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud e
0000000 00000000
Osaka, Japan
00000 As of 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Grifols Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Roche Holding Corporation Basel, Switzerland 000000 00000 00000000000
00000 Corporation Osaka, Japan 00000
000000 000000000 Corporation Oxford, United Kingdom 000 00000 00000000000 00000
0000 0000000 Corporation Bagsvaerd, Denmark 00000 000000000
000-000 0000000000 Corporation Hercules, CA 0000 00000000
You’re viewing 5 of 11 competitors. Get the full list »

Grifols Executive Team (20)

Name Title Board Seat Contact Info
Raimon Roura Co-Chief Executive Officer & Board Member
Víctor Grífols Deu Co-Chief Executive Officer & Board Member
Albert Coma-Cros President
Alberto Roura President
Antoni Fages President
You’re viewing 5 of 20 executive team members. Get the full list »

Grifols Board Members (12)

Name Representing Role Since
000é0 00000é0 00.0 Grifols Independent Director 000 0000
0ñ000 00000000 Grifols Lead Independent Director 000 0000
0000 000000000 Grifols Independent Director 000 0000
00000 000000 Grifols Board Member 000 0000
000000 00000 Grifols Co-Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Grifols Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Grifols Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Grifols‘s full profile, request access.

Request a free trial

Grifols Investments & Acquisitions (33)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 09-Mar-2021 000000000000000000 0000 Drug Discovery 0í0000 00í0000 000
000 000000 (00 00- 01-Mar-2021 000000000 00000 00 00000 Buildings and Property
00000000 01-Jan-2021 000000000000000000 00000 Drug Discovery 00000 0000
00000 0000000 (000 24-Nov-2020 00000 0000000 Biotechnology 0í0000 00í0000 000
MedKeeper 09-Nov-2020 Secondary Transaction - Private 000.00 Business/Productivity Software
You’re viewing 5 of 33 investments and acquisitions. Get the full list »

Grifols Subsidiaries (7)

Company Name Industry Location Founded
Alkahest Drug Discovery San Carlos, CA 2014
0000 00000000 Medical Supplies Arrasate, Spain 0000
0000000 Drug Discovery San Francisco, CA 0000
0000000 0000000 Biotechnology Zaragoza, Spain 0000
000000000 Business/Productivity Software Lakewood, CO 0000
You’re viewing 5 of 7 subsidiaries. Get the full list »

Grifols Exits (5)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000 000000 01-Aug-2018 000000000000000000 00000 Completed
  • 0000000
00000 04-Jun-2018 000000000000000000 00000 Completed
  • 0000000
00000000 17-May-2016 000000000 000.00 Completed
  • 0000000
0000000 19-Nov-2013 0000 000.00 Completed
  • 0000000
Celyad Oncology 03-Feb-2009 Early Stage VC 00.00 Completed
  • 3 buyers
To view Grifols’s complete exits history, request access »